Based on the substantial limitations with the submitted economic evaluation identified by CADTH:

• It is unclear whether the clinical efficacy data (i.e., Study 301, Study 302, and indirect treatment comparison [ITC]) which appears to have assessed halobetasol propionate (HP) 0.01% weight by weight (w/w) plus tazarotene (TAZ) 0.045% w/w as monotherapy in patients with more mild plaque psoriasis could be generalized to patients with moderate-to-severe plaque psoriasis, who are likely to be concurrently on systemic or biologic therapies.
• The comparative efficacy of HP/TAZ compared with other active topical therapies (including betamethasone dipropionate [BD] 0.5 mg/g and calcipotriol [CAL] 50 mcg/g) is uncertain.
• The cost-effectiveness of HP/TAZ compared with relevant comparators for the treatment of patients with moderate-to-severe plaque psoriasis remains uncertain.

CADTH reanalyses estimated that HP/TAZ is associated with a gain of 0.0004 quality-adjusted life-years (QALYs) compared with BD/CAL, resulting in an incremental cost-effectiveness ratio (ICER) of $85,670 per QALY. This estimate of the cost-effectiveness may be more representative of patients with a milder plaque psoriasis than the proposed indication, who are eligible to receive topical monotherapy and do not have access to phototherapy. CADTH illustrated that the ICERs are highly sensitive to changes in parameter values, and thus, the cost-effectiveness estimates for HP/TAZ in this setting should be interpreted with caution.

While the drug cost of HP/TAZ is less than the cost of the individual components based on a per gram list prices, HP/TAZ is more expensive than other relevant comparators such as BD/CAL.

Contents

• Abbreviations
• Executive Summary
  • Conclusions
• Stakeholder Input Relevant to the Economic Review
• Economic Review
  • Economic Evaluation
  • Issues for Consideration
  • Overall Conclusions
• Appendix 1. Cost Comparison Table
• Appendix 2. Submission Quality
• Appendix 3. Additional Information on the Submitted Economic Evaluation
• Appendix 4. Additional Details on the CADTH Reanalyses and Sensitivity Analyses of the Economic Evaluation
• References

Version: Final

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.